You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
As reported in April, revenues for the fiscal year ended March 31 totaled £16.6 million ($21.4 million), up from £8.9 million in FY2019.
Caspr's assay can be transported at room temperature and performed without complex external equipment, making it ideal for low-resource environments.
The decline was largely due to decreased testing volumes as a result of the COVID-19 pandemic, although there was improvement in pharma services.
The test is designed to detect immunoglobulin G, M, and A antibodies against SARS-CoV-2 using a single drop of whole blood, plasma, or serum.
The company reported $2.77 billion in revenues on the quarter, down from $2.88 billion in Q2 2019 but above the consensus Wall Street estimate of $2.5 billion.
The autoimmune diagnostics firm attributed the decline to lower testing volumes amid the SARS-CoV-2 pandemic and a decrease in average reimbursement per test.
The tube, cap, and multitube consumables enable SARS-CoV-2 tests on its automated Panther and Panther Fusion sample-to-answer molecular diagnostic systems.
Both PCR-based tests are designed to detect the SARS-CoV-2 nucleocapsid and ORF1ab genes, while Helix's assay also detects the virus' spike protein gene.
The firm said that it has begun developing its own products using synthetic affinity reagent technology acquired five years ago from the University of Leicester.
The assay is designed to detect immunoglobulin G and M antibodies against SARS-CoV-2 in human blood, plasma, and serum, with results provided in 15 minutes.
Magnolia said that the court found that its product claims were not misleading. However, Kurin's CEO said that over the years, Magnolia has displayed a pattern of exaggeration.
The firm currently has seven available products, including high- and low-throughput molecular tests and an antibody test for the virus.
Sanford Health will help validate TruGenomix's TruGen-1 post-traumatic stress disorder test through its Imagenetics clinical genomics program.
The firm's COVID-19 molecular offerings almost made up for the decline in routine testing resulting from the pandemic.
For the three months ended July 3, the Washington DC-based conglomerate recorded $5.30 billion in total sales compared to $4.44 billion in the year-ago period.
The test is aimed at detecting Zika antibodies in a highly specific way that avoids cross-reactivity with the dengue virus, according to the firm.
While Q2 revenues were down to $1.83 billion, the results represented a rebound from Q1 as the company saw expanded routine and SARS-CoV-2 testing.
The high-throughput PK7400 Automated Microplate System is designed for use in blood donor and plasma centers, as well as large reference laboratories.
The test is designed to detect the SARS-CoV-2 Orf1ab gene in upper respiratory specimens and sputum, according to the California-based company.
The proceeds from the round will allow the firm to begin selling its in vitro diagnostic blood test for patients with chronic kidney disease.